Patients with atherosclerotic cardiovascular disease (ASCVD) who have their Lp(a) measured are more likely to achieve recommended target LDL-C levels than those who do not have their Lp(a) measured, according to data from the PREVAIL study of Lp(a) testing in 55,427 patients with ASCVD in Australia.